BioSpace18h
Sarepta’s Elevidys Death, FDA’s Vaccine Move, Weldon Whiplash, PDUFAs in Cardio
Sarepta will update Elevidys’ label after a patient died following treatment; the FDA issues flu vaccine recommendations ...
StockStory.org on MSN1d
Why Sarepta Therapeutics (SRPT) Shares Are Sliding Today
Shares of biotech company Sarepta Therapeutics (NASDAQ:SRPT) fell 24.9% in the pre-market session after the company reported ...
Ticker: Sarepta reports death in drug trial; Google makes $32B cybersecurity deal
Cambridge-based Sarepta Therapeutics said Tuesday that a patient died while taking its closely watched gene therapy for ...
Investor's Business Daily on MSN1d
Sarepta's 27% Sell-Off Is 'Overblown,' 'Overdone' And 'Overly Bearish.' Here's Why It Happened.
Dystrophin helps keep muscles intact and functional.William Blair's Corwin noted two patients died following treatment with Novartis' Zolgensma, a treatment for spinal muscular atrophy."Overall, we ...
The American Journal of Managed Care14h
EMBARK Data Show Continued Improvements With DMD Gene Therapy
Data from the EMBARK trial of delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD) show that ...
Becker's Hospital Review16h
1st patient death in muscular dystrophy treatment
Cambridge, Mass.-based Sarepta Therapeutics reported the first known death from its Duchenne muscular dystrophy gene therapy ...